ArticleThe journal of pathology. Clinical research2026
Assessing the association between homologous recombination deficiency scores and treatment response in localized and metastatic prostate cancer.
Article in The journal of pathology. Clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The aim of this study was to evaluate the predictive value of homologous recombination deficiency scores for therapeutic efficacy in prostate cancer across various disease stages under different regimens. We collected tissue samples from 167 prostate cancer patients and performed genomic sequencing to assess homologous recombination deficiency scores. Among them, 67 patients with localized disease received radical prostatectomy, and 100 patients with metastatic disease received androgen receptor target inhibitor treatment. We examined the predictive value of homologous recombination deficiency scores in forecasting the therapeutic efficacy of standard-of-care treatment of prostate cancer under different disease stages. Among patients who underwent radical prostatectomy, those with higher homologous recombination deficiency scores experienced notably shorter biochemical progression-free survival and overall survival than those with lower scores (median biochemical progression-free survival: 50.6 versus 148.4 months, p = 0.037; median overall survival: 149.0 months versus not reached, p = 0.0018). In patients receiving androgen receptor pathway inhibitor treatment, men with higher homologous recombination deficiency scores exhibited reduced prostate-specific antigen progression-free survival, radiographic progression-free survival, and overall survival compared to the lower score group at the metastatic castration-resistant stage (median prostate-specific antigen progression-free survival: 8.17 versus 24.17 months, p = 0.032; median radiographic progression-free survival: 11.8 versus 24.8 months, p = 0.015; median overall survival: 36.5 months versus not reached, p = 0.056) and a deteriorating trend in the metastatic hormone-sensitive stage. Molecular characterization showed that higher homologous recombination deficiency scores were associated with higher alteration rates in genes such as BRCA2, CDK12, MYC, and PTEN. This study reveals that higher homologous recombination deficiency scores are associated with unfavorable treatment efficacy of radical prostatectomy in localized prostate cancer and of androgen receptor target inhibitor treatment in metastatic prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.